Circulating fibrosis biomarkers
| Test | Description | References |
| Indirect Fibrosis Biomarker Panels | ||
| AST:ALT ratio | AST (IU/L)/ALT (IU/L) | 128 |
| AST to platelet ratio index | AST (IU/L)/(ULN)/platelet count (x109/L) x 100 | 54 |
| BARD score | Weighted sum of BMI≥28 = 1 point, AST/ALT ratio ≥0.8 = 2 points, T2DM=1 | 129 |
| FIB-4 | Age x AST (IU/L)/platelet count (x109/L) x √ ALT (IU/L) | 130 131 |
| NAFLD fibrosis score | −1.675+0.037 x age (years)+0.094 x BMI (kg/m2)+1.13 x IFG or T2DM (yes=1, no=0)+0.99 x AST/ALT ratio − 0.013 x platelet (x109/L) − 0.66 x albumin (g/dL) | 53 |
| Direct fibrosis biomarker panels | ||
| ELF | ELF=−7.412 + (ln(HA)*0.681) + (ln(PIIINP)*0.775) + (ln(TIMP1)*0.494) | 60 132 |
| Fibro test | Patented algorithm combining total bilirubin, GGT, α2-macroglobulin, apolipoprotein A1, and haptoglobin, corrected for age and gender. | 133 134 |
| FibroMeter NAFLD | Patented algorithm combining age, body weight, glucose, AST, ALT, ferritin and platelet count | 135 136 |
| ADAPT | ADAPT=exp(log10((age x PRO-C3)/sqrt(Platelets)))+T2DM | 137–139 |
| FIBC3 | FIBC3=−5.939 + (0.053*age) + (0.076*BMI) + (1.614*T2DM) – (0.009*platelets) + (0.071*PRO-C3) | 138 139 |
| ABC3D | Age >50 = 1 point, BMI >30 = 1 point, platelet Count <200 = 1 point, PRO-C3 >15.5 = 1 point, T2DM=2 points | 138 139 |
AST:ALT, aspartate transaminase:alanine transaminase; BMI, body mass index; ELF, enhanced liver fibrosis; FIB-4, Fibrosis-4 index; IFG, impaired fasting glucose; NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus.